TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1202932

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no electro-acupuncture)
Number of subjects: 35
Study: 31271573

Group type: EXPERIMENTAL
Intervention: Tenectomy
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Superior oblique hang-back recession
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Superior oblique suture spacers
Number of subjects: 24
Study: 29178731

Group type: EXPERIMENTAL
Intervention: Manual toothbrush with tapered bristles (Oral‐B Super Thin Indicator toothbrush, OM159)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Marketed control toothbrush (Study 1: Oral‐B Complete Clean & Sensitive toothbrush; Study 2: Crest Pro‐Health Complete 7 Brush 35 toothbrush)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Marketed control toothbrush (Crest Pro‐Health Complete 7 Brush 35 toothbrush)
Number of subjects: 103
Study: 26212490

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 39

Group type: COMPARATOR
Intervention: Scaling and Root Planing (SRP)
Number of subjects: 39
Study: 23714676

Group type: EXPERIMENTAL
Intervention: Dexamethasone 21-phosphate encapsulated into autologous erythrocytes (n = 19)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham infusions (n = 18)
Number of subjects: 37
Study: 21436212

Group type: EXPERIMENTAL
Intervention: Spironolactone plus vitamin E (group 2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vitamin E (group 1)
Number of subjects: 20
Study: 18580547

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 11237

Group type: COMPARATOR
Intervention: Various types of NSAIDs including COX-2 NSAIDs
Number of subjects: 11237

Group type: COMPARATOR
Intervention: COX-2 NSAIDs
Number of subjects: 11237

Group type: COMPARATOR
Intervention: Selective COX-2 inhibitors
Number of subjects: 11237
Study: 16998290

Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg i.v. initially and 1 mg i.v. every 4 hours for 3 days)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Octreotide (continuous infusion of 25 microgram/h for 5 days)
Number of subjects: 88
Study: 12942351

Group type: EXPERIMENTAL
Intervention: Apicoectomy only (Group II)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (Group I)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Apicoectomy with retrograde seal using Ketac Fil (Group III)
Number of subjects: 51
Study: 11074150

Group type: EXPERIMENTAL
Intervention: Nasal nicotine spray (1-2mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Active placebo spray of oleoresin of pepper
Number of subjects: 11
Study: 9436145

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no spinal manipulation)
Number of subjects: 18
Study: 8513038

Group type: EXPERIMENTAL
Intervention: Fenfluramine (FF) 60 mg orally
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2877397

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant radiotherapy
Number of subjects: 230

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 230
Study: 30704429

Group type: EXPERIMENTAL
Intervention: Nordic foods complementary diet (lower protein content, increased fruits, vegetables, and fish)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Currently recommended Swedish complementary diet
Number of subjects: 0
Study: 26952318

Group type: EXPERIMENTAL
Intervention: Functional voice rehabilitation (SG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 20
Study: 26860800

Group type: EXPERIMENTAL
Intervention: Red ginseng (3.0 g/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 24176646

Group type: EXPERIMENTAL
Intervention: TAU+MCT
Number of subjects: 52

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 52
Study: 23156978

Group type: EXPERIMENTAL
Intervention: Nebulized terbinafine solution made with crushed tablet
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nebulized terbinafine solution made with raw drug powder
Number of subjects: 6
Study: 19029416

Group type: EXPERIMENTAL
Intervention: Structured QOL diary (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and the related lung cancer module LC13) completed weekly for 16 weeks
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 115
Study: 17545356

Group type: EXPERIMENTAL
Intervention: Growth hormone dosage of 0.11 IU/kg body weight per day
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Growth hormone dosage of 0.21 IU/kg body weight per day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 12921456

Group type: EXPERIMENTAL
Intervention: Pacifier sucking before milk feeding
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no pacifier before feeding)
Number of subjects: 36
Study: 11000734

Group type: EXPERIMENTAL
Intervention: ALM subgroup (lansoprazole + amoxicillin + metronidazole)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MLC subgroup (lansoprazole + metronidazole + clarithromycin)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ALC subgroup (lansoprazole + amoxicillin + clarithromycin)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ALM subgroup with initial metronidazole resistance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MLC subgroup with initial metronidazole resistance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ALC subgroup with initial metronidazole susceptibility
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ALM and MLC subgroups (metronidazole)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ALC and MLC subgroups (clarithromycin)
Number of subjects: 100
Study: 8834030

Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg/day) and ursodeoxycholic acid
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid alone
Number of subjects: 22
Study: 1468087

Group type: EXPERIMENTAL
Intervention: Magnesium chloride solution
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Slow-release magnesium chloride tablets
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Magnesium gluconate tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: All supplements
Number of subjects: 12
Study: 6378439

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3002735

Group type: EXPERIMENTAL
Intervention: Sulbactam with ampicillin (1 gm with 1 gm)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Cefoxitin (2 gm)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Sulbactam with ampicillin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study: 30463622

Group type: EXPERIMENTAL
Intervention: High-intensity NPPV
Number of subjects: 600

Group type: COMPARATOR
Intervention: Low-intensity NPPV
Number of subjects: 600
Study: 28919843

Group type: EXPERIMENTAL
Intervention: Phenylalanine (3 g/dose)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 25926507

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei 431 (≥10^9 CFU)
Number of subjects: 1104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1104
Study: 23053130

Group type: COMPARATOR
Intervention: Continuous Resistance Training (CTR)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Periodic Resistance Training (PTR)
Number of subjects: 14
Study: 20657774

Group type: EXPERIMENTAL
Intervention: Structured case record form (CRF) interviews
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Coital diaries (CD)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: In-depth interviews (IDI)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Triangulation model
Number of subjects: 725
Study: 18260773

Group type: EXPERIMENTAL
Intervention: FreeStyle Flash
Number of subjects: 202

Group type: COMPARATOR
Intervention: Accu-Chek Advantage
Number of subjects: 202

Group type: COMPARATOR
Intervention: Accu-Chek Compact Plus
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Ascensia Contour
Number of subjects: 202

Group type: COMPARATOR
Intervention: BD Logic
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: FreeStyle Flash (second group)
Number of subjects: 202

Group type: COMPARATOR
Intervention: All meters
Number of subjects: 202

Group type: COMPARATOR
Intervention: Accu-Chek Advantage, Accu-Chek Compact Plus, BD Logic
Number of subjects: 202
Study: 16364566

Group type: EXPERIMENTAL
Intervention: Strengths based case management
Number of subjects: 245

Group type: COMPARATOR
Intervention: Passive referral
Number of subjects: 245
Study: 12675760

Group type: EXPERIMENTAL
Intervention: 2 ml of 1:1000 nebulized adrenaline
Number of subjects: 75

Group type: COMPARATOR
Intervention: 2 ml of nebulized normal saline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nebulized adrenaline
Number of subjects: 75
Study: 10744272

Group type: EXPERIMENTAL
Intervention: Aggressive fluid resuscitation strategy
Number of subjects: 34
Study: 9186254

Group type: EXPERIMENTAL
Intervention: Childhood-onset epilepsy (epilepsy only)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Antiepileptic polytherapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Continuing seizures
Number of subjects: 100

Group type: COMPARATOR
Intervention: Random controls
Number of subjects: 100

Group type: COMPARATOR
Intervention: Employee controls
Number of subjects: 100
Study: 1546154

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 28613407

Group type: EXPERIMENTAL
Intervention: iCBT intervention group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 29986695

Group type: EXPERIMENTAL
Intervention: Computer-generated individualized feedback letters at baseline, month 3, and month 6.
Number of subjects: 1648

Group type: COMPARATOR
Intervention: Assessment only (Control group).
Number of subjects: 1648
Study: 27276401

Group type: EXPERIMENTAL
Intervention: α-lipoic acid (ALA) at 600-1800 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 25876343

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment (acupoint injection + neural electrical stimulation)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Acupoint injection
Number of subjects: 183

Group type: COMPARATOR
Intervention: Neural electrical stimulation
Number of subjects: 183

Group type: COMPARATOR
Intervention: Swallowing training
Number of subjects: 183

Group type: COMPARATOR
Intervention: Blank control group
Number of subjects: 183
Study: 22832365

Group type: EXPERIMENTAL
Intervention: Decompressive surgery (DS) for malignant middle cerebral artery infarcts
Number of subjects: 31
Study: 20458350

Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/day for 4 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Alfacalcidol (0.5 microg/day for 4 months)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/day for 2 months after crossover)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Alfacalcidol (0.5 microg/day for 2 months after crossover)
Number of subjects: 44
Study: 18479174

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO)
Number of subjects: 88
Study: 16077385

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg . kg ‐1) during induction of anesthesia
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 34
Study: 12663440

Group type: EXPERIMENTAL
Intervention: Quinine (30 mg/kg/day continuous intravenous infusion) in combination with induction chemotherapy (idarubicine and cytarabine)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 425

Group type: COMPARATOR
Intervention: Induction chemotherapy (idarubicine and cytarabine) with or without quinine
Number of subjects: 425
Study: 10731406

Group type: EXPERIMENTAL
Intervention: JPEG compression ratio 10:1
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: JPEG compression ratio 16:1
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: JPEG compression ratio 6:1
Number of subjects: 48

Group type: COMPARATOR
Intervention: JPEG compression ratio 1:1 (uncompressed)
Number of subjects: 48
Study: 8707499

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1643937

Group type: EXPERIMENTAL
Intervention: 4-hour oxygen withdrawal
Number of subjects: 6

Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 6
Study: 6439408

Group type: EXPERIMENTAL
Intervention: DDP-MECY (methotrexate-leucovorin plus cyclophosphamide)
Number of subjects: 33

Group type: COMPARATOR
Intervention: DDP-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and DDP)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: DDP-MECY
Number of subjects: 33

Group type: COMPARATOR
Intervention: DDP-CHAD
Number of subjects: 33
Study: 31361094

Group type: EXPERIMENTAL
Intervention: deoxyribonucleate sodium (75 mg via intramuscular injection every 48 hours for 1 month)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (standard therapy without deoxyribonucleate sodium)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: deoxyribonucleate sodium
Number of subjects: 62
Study: 27964837

Group type: EXPERIMENTAL
Intervention: Sitagliptin plus basal insulin (glargine once daily)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Basal-bolus regimen (glargine once daily and rapid-acting insulin before meals)
Number of subjects: 279
Study: 25942458

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg two times a day for 7 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg once a day for 7 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of atorvastatin 20 mg once a day + raltegravir 400 mg two times a day for 7 days
Number of subjects: 24
Study: 24991090

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 37

Group type: COMPARATOR
Intervention: PI/NNRTI
Number of subjects: 37
Study: 22029869

Group type: EXPERIMENTAL
Intervention: 4-haptic angulated (FA) intraocular lens (IOL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2-haptic non-angulated (TNA) intraocular lens (IOL)
Number of subjects: 40
Study: 20137416

Group type: EXPERIMENTAL
Intervention: levofloxacin 0.5%
Number of subjects: 150

Group type: COMPARATOR
Intervention: gatifloxacin 0.3%
Number of subjects: 150

Group type: COMPARATOR
Intervention: levofloxacin 0.3%
Number of subjects: 150
Study: 17352026

Group type: EXPERIMENTAL
Intervention: Low-dose regimen (group A): omeprazole 20 mg b.i.d, clarithromycin 250 mg b.i.d, amoxicillin 500 mg b.i.d
Number of subjects: 160

Group type: COMPARATOR
Intervention: High-dose regimen (group B): omeprazole 20 mg b.i.d, clarithromycin 500 mg b.i.d, amoxicillin 1000 mg b.i.d
Number of subjects: 160
Study: 15449576

Group type: EXPERIMENTAL
Intervention: Special nutritional formula providing 480 kcal, 31 g proteins, 120 IU vitamin E, 3.8 microg vitamin B12, 400 microg folic acid, 10(9) cfu Lactobacillus paracasei (NCC 2461), and 6 g of fructo‐oligosaccharides
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonsupplemented individuals
Number of subjects: 60
Study: 11678298

Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone acetate injection with local anesthetic (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Physical therapy measures plus nonsteroidal anti‐inflammatory drugs (group B)
Number of subjects: 20
Study: 9395778

Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate, 8 mg/ml, one drop instilled at 7 AM and repeated on alternate hours throughout the day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate, 8 mg/ml
Number of subjects: 20
Study: 7734028

Group type: EXPERIMENTAL
Intervention: Levosulpiride (75 mg/day for 20 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2438613

Group type: EXPERIMENTAL
Intervention: Combined chemo‐radiotherapy (2 X COPP/ABVD + 40 Gy EF)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Combined chemo‐radiotherapy (2 X COPP/ABVD + 20 Gy IF)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (3 X COPP/ABVD) followed by consolidation by radiotherapy (20 Gy IF)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Induction chemotherapy (3 X COPP/ABVD) followed by consolidation by chemotherapy (1 X COPP/ABVD)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Salvage therapy (radiotherapy in case of persisting nodal disease; chemotherapy with 4 X CEVD in case of persisting disseminated disease)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Consolidation therapy
Number of subjects: 358
Study: 29856832

Group type: EXPERIMENTAL
Intervention: Modest fixed-value payment per exercise session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced incentives to exercise more frequently
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced financial incentive to increase exercise duration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard payment group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobic fitness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity and body composition
Number of subjects: 0
Study: 28452705

Group type: EXPERIMENTAL
Intervention: Normal saline solution nasal-pharyngeal irrigation (NSNPI) for 30 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluticasone propionate nasal spray (FPNS) for 30 days
Number of subjects: 50
Study: 24646362

Group type: EXPERIMENTAL
Intervention: Polyphenon E 400 mg, 600 mg, and 800 mg (combined)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Polyphenon E (all doses combined)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 23513000

Group type: EXPERIMENTAL
Intervention: HD ProCore(™) needle
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard 22-gauge needle
Number of subjects: 36
Study: 22055587

Group type: EXPERIMENTAL
Intervention: PEI-RFA
Number of subjects: 90

Group type: COMPARATOR
Intervention: RFA alone
Number of subjects: 90

Group type: COMPARATOR
Intervention: PEI alone
Number of subjects: 90
Study: 19004596

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture as an adjunct to methadone detoxification
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard methadone detoxification treatment (Control)
Number of subjects: 83
Study: 17531569

Group type: EXPERIMENTAL
Intervention: Very high hs‐CRP levels (>7.5 mg/L)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Very low hs‐CRP levels (<=1 mg/L)
Number of subjects: 80
Study: 15620225

Group type: EXPERIMENTAL
Intervention: Periodic waveforms
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Single repetitions of a piece of the waveform
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Auditory sensory memory
Number of subjects: 5
Study: 11729476

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (M-VAC: methotrexate, vinblastine, adriamycin, cisplatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radical cystectomy
Number of subjects: 0
Study: 9930484

Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia followed by warm reperfusion
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegia followed by warm reperfusion
Number of subjects: 105

Group type: COMPARATOR
Intervention: Cold blood cardioplegia with no reperfusion
Number of subjects: 105
Study: 8683846

Group type: EXPERIMENTAL
Intervention: Oral vitamin A capsules given to 42 children
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group of 53 children
Number of subjects: 101
Study: 2181843

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Surgical treatment (coronary bypass surgery)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Internal thoracic (mammary) artery grafting
Number of subjects: 797

Group type: COMPARATOR
Intervention: Vein grafts only
Number of subjects: 797

Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 797
Study: 7000170

Group type: EXPERIMENTAL
Intervention: Acyclovir 2% ointment 5 times a day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Idoxuridine 1% ointment 5 times a day
Number of subjects: 60
Study: 30813612

Group type: EXPERIMENTAL
Intervention: Energy restricted diets and/or exercise interventions
Number of subjects: 221
Study: 28814158

Group type: EXPERIMENTAL
Intervention: oxymorphone patches + capsaicin
Number of subjects: 15

Group type: COMPARATOR
Intervention: oxymorphone patches - capsaicin
Number of subjects: 15
Study: 25885807

Group type: EXPERIMENTAL
Intervention: Structured smoking cessation program delivered by trained ambulatory pharmacists (at least four sessions face-to-face)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unstructured brief smoking cessation advice (5 to 10 min) given by the pharmacist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups offered nicotine replacement therapy if feasible
Number of subjects: 0
Study: 25582987

Group type: EXPERIMENTAL
Intervention: MobileMums
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control
Number of subjects: 263
Study: 22637738

Group type: EXPERIMENTAL
Intervention: Hypertrophy resistance training (HRT) - 2 sets, 10-12 repetitions, 70% of one-repetition maximum (1-RM)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Endurance resistance training (ERT) - 2 sets, 25-30 repetitions, 40% of one-repetition maximum (1-RM)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both HRT and ERT (combined with aerobic exercise training)
Number of subjects: 32
Study: 22008920

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 45

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 45
Study: 18074296

Group type: EXPERIMENTAL
Intervention: Carbohydrate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Carbohydrate + Protein
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 16468059

Group type: EXPERIMENTAL
Intervention: Three-parameter models
Number of subjects: 17

Group type: COMPARATOR
Intervention: Two-parameter models
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Critical velocity (CV)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combination of CV with other parameters
Number of subjects: 17